Janssen, Theravance in deal for intestinally-restricted JAK inhibitor

The Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) and Theravance Biopharma Inc. (NASDAQ:TBPH) entered into a deal to co-develop and commercialize Theravance's pan-Janus kinase (JAK) inhibitor TD-1473 and related

Read the full 313 word article

User Sign In